Inventor · disambiguated record
Chrystelle Brignone
Also filed as: BRIGNONE CHRYSTELLE
7 granted patents·8 pending applications·60 citations·filing 2015–2025
83Inventor score
Top patents by PatentIndex Score
15 records- 0198US10711060B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Jul 14, 2020·29 cites·5 claims
- 0296US9908936B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Mar 6, 2018·23 cites·30 claims
- 0393US10940181B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2020·Granted Mar 9, 2021·3 cites·9 claims
- 0489US10874713B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2016·Granted Dec 29, 2020·4 cites·17 claims
- 0586US11684654B2Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2020·Granted Jun 27, 2023·1 cites·10 claims
- 0682US2023330182A1Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2023·Application pending·0 cites
- 0779US2023074746A1Combined preparations for the treatment of cancer or infectionIMMUTEP SAS·Filed 2022·Application pending·0 cites
- 0875US2025382365A1Antibody molecules to lag-3 and uses thereofNOVARTIS AG·Filed 2025·Application pending·0 cites
- 0973US12252535B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Mar 18, 2025·0 cites·10 claims
- 1071US2023272107A1Anti-lag-3 antibodiesIMMUTEP SAS·Filed 2023·Application pending·0 cites
- 1153US2015259420A1Antibody molecules to lag-3 and uses thereofNOVARTIS AG·Filed 2015·Application pending·0 cites
- 1251US11680104B2Anti-LAG-3 antibodiesIMMUTEP SAS·Filed 2016·Granted Jun 20, 2023·0 cites·7 claims
- 1351US2022220199A1Anti-lag-3 binding moleculesIMMUTEP SAS·Filed 2020·Application pending·0 cites
- 1450US2022341913A1AssaysIMMUTEP SAS·Filed 2020·Application pending·0 cites
- 1540US2018340025A1Combination therapies comprising antibody molecules to lag-3NOVARTIS AG·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →